BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1579296)

  • 1. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
    Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
    Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
    Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF
    Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of Ca 125 levels during primary therapy.
    Markmann S; Gerber B; Briese V
    Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
    Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
    J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
    Reiter W; Stieber P; Reuter C; Nagel D; Cramer C; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
    Kang S; Seo SS; Park SY
    J Surg Oncol; 2009 Sep; 100(3):244-7. PubMed ID: 19267361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
    Lundin J; Roberts PJ; Kuusela P; Haglund C
    Anticancer Res; 1995; 15(5B):2181-6. PubMed ID: 8572621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.
    Hefler LA; Concin N; Hofstetter G; Marth C; Mustea A; Sehouli J; Zeillinger R; Leipold H; Lass H; Grimm C; Tempfer CB; Reinthaller A
    Clin Cancer Res; 2008 Feb; 14(3):710-4. PubMed ID: 18245530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
    Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
    Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
    van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
    Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.